| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Osamu Kano, Hirono Ito, Takanori Takazawa, Yuji Kawase, Kiyoko Murata, Konosuke Iwamoto, Tetsuro Nagaoka, Takehisa Hirayama, Ken Miura, Riya Nagata, Tetsuhito Kiyozuka, Jo Aoyagi, Ryuta Sato, Teruo Eguchi, Ken Ikeda, Yasuo Iwasak. Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil. Neuropsychiatric disease and treatment. vol 9. 2013-07-04. PMID:23431041. |
clinical trials have shown the benefits of acetylcholinesterase inhibitors, such as donepezil and galantamine, and an n-methyl-d-aspartate receptor antagonist, memantine, in patients with alzheimer's disease (ad). |
2013-07-04 |
2023-08-12 |
Not clear |
| Eda Özturan Özer, Oya Unsal Tan, Keriman Ozadali, Tuba Küçükkılınç, Ayla Balkan, Gülberk Uça. Synthesis, molecular modeling and evaluation of novel N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and Aβ aggregation. Bioorganic & medicinal chemistry letters. vol 23. issue 2. 2013-07-01. PMID:23273219. |
to develop new drugs for treatment of alzheimer's disease, a group of n'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazones was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-42). |
2013-07-01 |
2023-08-12 |
Not clear |
| Liang Ye, Fenghua Fu, Wanhui Liu, Kaoxiang Sun, Youxin Li, Jie He, Xin Yu, Pengfei Yu, Jingwei Tia. Preparation and in vitro and in vivo evaluation of HupA PLGA microsphere. Pakistan journal of pharmaceutical sciences. vol 26. issue 2. 2013-06-18. PMID:23455202. |
acetylcholinesterase inhibitors (acheis), including huperzine a (hupa), have been the mainstay of treatment for alzheimer's disease (ad). |
2013-06-18 |
2023-08-12 |
rat |
| E Zurek, P Szymański, E Mikiciuk-Olasi. Synthesis and biological activity of new donepezil-hydrazinonicotinamide hybrids. Drug research. vol 63. issue 3. 2013-06-17. PMID:23447117. |
currently available treatment used in alzheimer's disease is based on acetylcholinesterase inhibitors, e. g. donepezil, tacrine, galantamine, and rivastigmine. |
2013-06-17 |
2023-08-12 |
Not clear |
| Claudio Babiloni, Claudio Del Percio, Regis Bordet, Jean-Luis Bourriez, Marina Bentivoglio, Pierre Payoux, Philippe Derambure, Sophie Dix, Francesco Infarinato, Roberta Lizio, Antonio Ivano Triggiani, Jill C Richardson, Paolo M Rossin. Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. vol 124. issue 5. 2013-06-12. PMID:23098644. |
effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in alzheimer's disease patients. |
2013-06-12 |
2023-08-12 |
Not clear |
| Claudio Babiloni, Claudio Del Percio, Regis Bordet, Jean-Luis Bourriez, Marina Bentivoglio, Pierre Payoux, Philippe Derambure, Sophie Dix, Francesco Infarinato, Roberta Lizio, Antonio Ivano Triggiani, Jill C Richardson, Paolo M Rossin. Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. vol 124. issue 5. 2013-06-12. PMID:23098644. |
acetylcholinesterase inhibitors (acheis) are the most widely used symptomatic treatment for mild to severe alzheimer's disease (ad) patients, while n-methyl-d-aspartic acid (nmda) receptor antagonist memantine is licensed for use in moderate to severe ad patients. |
2013-06-12 |
2023-08-12 |
Not clear |
| Jason M Uslaner, Donnie Eddins, Vanita Puri, Christopher E Cannon, Jane Sutcliffe, Chan Sing Chew, Michelle Pearson, Jeffrey A Vivian, Ronald K Chang, William J Ray, Scott D Kuduk, Marion Wittman. The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. Psychopharmacology. vol 225. issue 1. 2013-06-10. PMID:22825578. |
the current standards of care for alzheimer's disease, acetylcholinesterase inhibitors, have limited efficacy due to a host of mechanism-related side effects arising from indiscriminate activation of muscarinic and nicotinic receptors. |
2013-06-10 |
2023-08-12 |
rat |
| Alessandra Marcone, Valentina Garibotto, Rosa Maria Moresco, Ioana Florea, Andrea Panzacchi, Assunta Carpinelli, Jere R Virta, Marco Tettamanti, Barbara Borroni, Alessandro Padovani, Alessandra Bertoldo, Karl Herholz, Juha O Rinne, Stefano Francesco Cappa, Daniela Peran. [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer's disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis. Journal of Alzheimer's disease : JAD. vol 31. issue 2. 2013-06-04. PMID:22596267. |
non-invasive approaches for positron emission tomography (pet) parametric imaging of acetylcholinesterase (ache) activity have been developed and applied to the investigation of dementia, mainly alzheimer's disease (ad), but also dementia with lewy bodies (dlb), not including, however, patients in the early disease stage. |
2013-06-04 |
2023-08-12 |
human |
| Francisco Prado-Prado, Xerardo García-Mera, Manuel Escobar, Nerea Alonso, Olga Caamaño, Matilde Yañez, Humberto González-Día. 3D MI-DRAGON: new model for the reconstruction of US FDA drug- target network and theoretical-experimental studies of inhibitors of rasagiline derivatives for AChE. Current topics in medicinal chemistry. vol 12. issue 16. 2013-06-04. PMID:23030618. |
an important protein in this sense is the acetylcholinesterase (ache), which is the target of many alzheimer's dementia drugs. |
2013-06-04 |
2023-08-12 |
Not clear |
| Daiane Priscila Simão-Silva, Paulo Henrique Ferreira Bertolucci, Roger William de Labio, Spencer Luiz Marques Payão, Lupe Furtado-Alle, Ricardo Lehtonen Rodrigues Souz. Association analysis between K and -116A variants of butyrylcholinesterase and Alzheimer's disease in a Brazilian population. Chemico-biological interactions. vol 203. issue 1. 2013-05-28. PMID:23022600. |
in alzheimer's disease (ad) a reduction in acetylcholinesterase (ache) and an increase in butyrylcholinesterase (bche) activity are observed. |
2013-05-28 |
2023-08-12 |
human |
| Kevin B Temeyer, Alexander P Tuckow, Danett K Brake, Andrew Y Li, Adalberto A Pérez de Leó. Acetylcholinesterases of blood-feeding flies and ticks. Chemico-biological interactions. vol 203. issue 1. 2013-05-28. PMID:23036311. |
acetylcholinesterase (ache) is the biochemical target of organophosphate (op) and carbamate pesticides for invertebrates, vertebrate nerve agents, and ache inhibitors used to reduce effects of alzheimer's disease. |
2013-05-28 |
2023-08-12 |
human |
| Christopher Hyde, Jaime Peters, Mary Bond, Gabriel Rogers, Martin Hoyle, Rob Anderson, Mike Jeffreys, Sarah Davis, Praveen Thokala, Tiffany Moxha. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. Age and ageing. vol 42. issue 1. 2013-05-24. PMID:23179169. |
evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for alzheimer's disease: systematic review and economic model. |
2013-05-24 |
2023-08-12 |
Not clear |
| Rafael Stryjer, Dana Ophir, Faina Bar, Baruch Spivak, Abraham Weizman, Rael D Strou. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clinical neuropharmacology. vol 35. issue 4. 2013-05-23. PMID:22751086. |
this study examined the effects of rivastigmine, a selective central nervous system acetylcholinesterase inhibitor, with benefits on cognition in alzheimer disease, on memory performance in patients with schizophrenia treated with ect. |
2013-05-23 |
2023-08-12 |
human |
| Marco Catto, Leonardo Pisani, Francesco Leonetti, Orazio Nicolotti, Paolo Pesce, Angela Stefanachi, Saverio Cellamare, Angelo Carott. Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorganic & medicinal chemistry. vol 21. issue 1. 2013-05-21. PMID:23199476. |
acetylcholinesterase inhibitors (acheis) are currently the drugs of choice, although only symptomatic and palliative, for the treatment of alzheimer's disease (ad). |
2013-05-21 |
2023-08-12 |
Not clear |
| Kamyar Mollazadeh-Moghaddam, Arsia Jamali, Fatemeh Adili-Aghdam, Shahin Akhondzade. Delirium associated with donepezil in a patient with Alzheimer's disease: a case report. Iranian journal of psychiatry. vol 8. issue 1. 2013-05-20. PMID:23682254. |
donepezil, a member of the acetylcholinesterase inhibitor family, is approved for management of cognitive impairments as well as behavioral complications in patients with neurodegenerative alzheimer's disease. |
2013-05-20 |
2023-08-12 |
Not clear |
| Pran Kishore Deb, Anuradha Sharma, Poonam Piplani, Raghuram Rao Akkinepall. Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors. Molecular diversity. vol 16. issue 4. 2013-05-16. PMID:22996404. |
the reversible inhibition of acetylcholinesterase (ache) has become a promising target for the treatment of alzheimer's disease (ad) which is mainly associated with low in vivo levels of acetylcholine (ach). |
2013-05-16 |
2023-08-12 |
Not clear |
| Diego Albani, Filippo Martinelli Boneschi, Gloria Biella, Giacomo Giacalone, Sara Lupoli, Francesca Clerici, Luisa Benussi, Roberta Ghidoni, Daniela Galimberti, Rosanna Squitti, Stefania Mariani, Annamaria Confaloni, Giuseppe Bruno, Claudio Mariani, Elio Scarpini, Giuliano Binetti, Giuseppe Magnani, Massimo Franceschi, Gianluigi Forlon. Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients. Journal of Alzheimer's disease : JAD. vol 30. issue 4. 2013-05-15. PMID:22465999. |
alzheimer's disease (ad) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. |
2013-05-15 |
2023-08-12 |
Not clear |
| Jonathan J Sabbagh, Chelcie F Heaney, Monica M Bolton, Andrew S Murtishaw, Jennifer A Ure, Jefferson W Kinne. Administration of donepezil does not rescue galanin-induced spatial learning deficits. The International journal of neuroscience. vol 122. issue 12. 2013-05-07. PMID:22897394. |
the current study investigated if donepezil, an acetylcholinesterase inhibitor utilized in alzheimer's disease, could rescue galanin-induced morris water task deficits in rats. |
2013-05-07 |
2023-08-12 |
rat |
| Mehmet Sofuoglu, Aryeh I Herman, Yisheng Li, Andrew J Water. Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. Psychopharmacology. vol 224. issue 3. 2013-04-29. PMID:22700039. |
galantamine (gal), a reversible and competitive inhibitor of acetylcholinesterase, is used clinically in the treatment of alzheimer's dementia. |
2013-04-29 |
2023-08-12 |
Not clear |
| E L Konrath, B M Neves, C Dos S Passos, P S Lunardi, M G Ortega, J L Cabrera, C A Gonçalves, A T Henrique. Huperzia quadrifariata and Huperzia reflexa alkaloids inhibit acetylcholinesterase activity in vivo in mice brain. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 19. issue 14. 2013-04-26. PMID:23022390. |
huperzine a, a lycopodium alkaloid produced by chinese folk herb huperzia serrata (lycopodiaceae), has been shown to be a promising agent for the treatment of alzheimer's disease due to its potent acetylcholinesterase (ache) activity, as well its efficacy in the treatment of memory of aged patients. |
2013-04-26 |
2023-08-12 |
mouse |